(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 74.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Autolus Therapeutics's revenue in 2025 is $51,128,000.On average, 13 Wall Street analysts forecast AUTL's revenue for 2025 to be $20,418,779,045, with the lowest AUTL revenue forecast at $18,635,619,029, and the highest AUTL revenue forecast at $22,356,036,024. On average, 13 Wall Street analysts forecast AUTL's revenue for 2026 to be $39,069,834,385, with the lowest AUTL revenue forecast at $28,621,048,976, and the highest AUTL revenue forecast at $50,106,796,455.
In 2027, AUTL is forecast to generate $76,250,051,439 in revenue, with the lowest revenue forecast at $51,381,622,795 and the highest revenue forecast at $136,872,169,124.